Nuvectis Pharma, Inc.
NVCT
$18.96
-$0.27-1.40%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -26.19% | -34.72% | -39.17% | -30.98% | -4.57% |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 20.24% | 32.13% | 24.17% | 15.39% | 9.94% |
| Change in Net Operating Assets | -56.69% | -27.40% | 132.24% | 543.35% | 147.70% |
| Cash from Operations | -57.21% | -52.08% | -30.72% | -6.37% | 14.25% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -32.80% | -39.88% | 159.31% | 288.64% | 165.43% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 72.38% | 46.98% | -449.74% | -785.12% | -183.78% |
| Cash from Financing | -29.45% | -39.40% | 149.79% | 274.89% | 163.98% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -153.39% | -145.52% | 2,309.27% | 473.68% | 233.82% |